[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551922":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":48,"responsibleParty":183,"collaborators":185,"id":189,"slug":190,"hasResults":191,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":191,"sex":197,"minAge":198,"maxAge":26,"enrollmentInfo":199,"targetDuration":26,"studyType":202,"phases":203,"briefSummary":205,"conditions":206,"keywords":211,"overallStatus":51,"whyStopped":26,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"Swiss GO Trial Group","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","ACTIVE_COMPARATOR","Physicians and patients randomized to the SOC arm will not receive the treatment recommendation of the mTB and thus will undergo the standard treatment consisting of 2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg\u002Fm2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg\u002Fm2 weekly.\n\nEither q3w regime or q1w regime.",[13],"Drug: Carboplatin \u002F Paclitaxel Chemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Interventional Arm","EXPERIMENTAL","The intervention studied is a treatment recommendation by a specialized molecular tumorboard. This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs\u002F experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.",[19],"Other: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"OTHER","Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling","The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs\u002F experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Carboplatin \u002F Paclitaxel Chemotherapy","2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg\u002Fm2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg\u002Fm2 weekly",[9],[33],"Standard of care chemotherapy regime",[35],{"name":36,"affiliation":37,"role":38},"Viola Heinzelmann-Schwarz, Prof.","University Hospital Basel, Head Women's Hospital","PRINCIPAL_INVESTIGATOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":26,"email":44},"Maren S Vogel, PhD","CONTACT","+41 61 3284203","maren.vogel@usb.ch",{"name":46,"role":42,"phone":43,"phoneExt":26,"email":47},"Team Swiss GO Trial Group","pm-team@swiss-go.ch",[49,72,91,110,129,147,165],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Kantonsspital Baden AG","RECRUITING","Baden","Canton of Aargau","5404","Switzerland","CH",{"type":58,"coordinates":59},"Point",[60,61],8.30592,47.47333,{"lat":61,"lon":60},[64,68],{"name":65,"role":42,"phone":66,"phoneExt":26,"email":67},"Martin Heubner, Prof","+ 41 56 486 35 02","martin.heubner@ksb.ch",{"name":69,"role":42,"phone":70,"phoneExt":26,"email":71},"Carina Rofner","+41 56 486 36 32","Carina.Rofner@ksb.ch",{"facility":73,"status":51,"city":74,"state":75,"zip":76,"country":55,"countryCode":56,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Universitätsspital Basel","Basel","Canton of Basel-City","4031",{"type":58,"coordinates":78},[79,80],7.57327,47.55839,{"lat":80,"lon":79},[83,87],{"name":84,"role":42,"phone":85,"phoneExt":26,"email":86},"Viola Heinzelmann-Schwarz, Prof","+41 (0)61 265 58 83","viola.heinzelmann@usb.ch",{"name":88,"role":42,"phone":89,"phoneExt":26,"email":90},"Antje Michel, PhD","+41 61 32 84214","antje.michel@usb.ch",{"facility":92,"status":51,"city":93,"state":94,"zip":95,"country":55,"countryCode":56,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"HOCH Health Ostschweiz Kantonsspital St.Gallen","Sankt Gallen","Canton of St. Gallen","9007",{"type":58,"coordinates":97},[98,99],9.37477,47.42391,{"lat":99,"lon":98},[102,106],{"name":103,"role":42,"phone":104,"phoneExt":26,"email":105},"Jens Huober, Prof","+41 494 11 11","Jens.Huober@h-och.ch",{"name":107,"role":42,"phone":108,"phoneExt":26,"email":109},"Julia Kern","+41 71 494 64 52","Julia.Kern@h-och.ch",{"facility":111,"status":51,"city":112,"state":113,"zip":114,"country":55,"countryCode":56,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Thurgau AG Frauenfeld \u002F Münsterlingen","Frauenfeld","Thurgau","8500",{"type":58,"coordinates":116},[117,118],8.89893,47.55776,{"lat":118,"lon":117},[121,125],{"name":122,"role":42,"phone":123,"phoneExt":26,"email":124},"Mathias Fehr, Prof","+41 (0) 58 144 7255","mathias.fehr@stgag.ch",{"name":126,"role":42,"phone":127,"phoneExt":26,"email":128},"Daniela Berner","+41 58 144 1729","daniela.berner@stgag.ch",{"facility":130,"status":51,"city":131,"state":26,"zip":132,"country":55,"countryCode":56,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Inselspital Bern (University Hospital for Medical Oncology)","Bern","3010",{"type":58,"coordinates":134},[135,136],7.44744,46.94809,{"lat":136,"lon":135},[139,143],{"name":140,"role":42,"phone":141,"phoneExt":26,"email":142},"Julian Wampfler","+41 (0)31 632 5059","julian.wampfler@insel.ch",{"name":144,"role":42,"phone":145,"phoneExt":26,"email":146},"Anke Klingenberg-Rettich","+41 (0)31 632 19 28","Anke.Klingenberg-Rettich@insel.ch",{"facility":148,"status":51,"city":149,"state":26,"zip":150,"country":55,"countryCode":56,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"HFR-Fribourg- Hopital Cantonal","Fribourg","1708",{"type":58,"coordinates":152},[153,154],7.15128,46.80237,{"lat":154,"lon":153},[157,161],{"name":158,"role":42,"phone":159,"phoneExt":26,"email":160},"Vérène Dougoud-Chauvin, Dr. med.","+41(0)26 306.22 60","Verene.Dougoud-Chauvin@h-fr.ch",{"name":162,"role":42,"phone":163,"phoneExt":26,"email":164},"Mirelle Maître","+41(0)26 306 22 75","Mireille.Maitre@h-fr.ch",{"facility":166,"status":51,"city":167,"state":26,"zip":168,"country":55,"countryCode":56,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"University Hospital Zurich","Zurich","8091",{"type":58,"coordinates":170},[171,172],8.55,47.36667,{"lat":172,"lon":171},[175,179],{"name":176,"role":42,"phone":177,"phoneExt":26,"email":178},"Eleftherios Pierre Samartzis, Dr . med.","+41 (0) 43 253 09 62","eleftherios.samartzis@usz.ch",{"name":180,"role":42,"phone":181,"phoneExt":26,"email":182},"Isabel Breyer, PhD","+41 44 255 56 29","isabel.breyer@usz.ch",{"type":184,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[186],{"name":187,"class":188},"Tumor Profiler Center Switzerland","UNKNOWN","100551922","ov-precision-study-examining-the-benefit-of-a-tumor--and-patient-specific-cancer-therapy-100551922",false,"NCT06466382","OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy","OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.","OVPrecision","Inclusion Criteria:\n\n* Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV\n* No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis\n* Envisaged surgical candidate for interval debulking after 2 cycles of treatment\n* Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures\n* ECOG 0-2\n* Written informed consent according to national legal and regulatory requirements prior to any project specific procedures\n\nExclusion Criteria:\n\n* Elevated liver enzymes (double of normal range: ASAT \\> 68 U\u002Fl; ALAT \\> 82 U\u002Fl; GGT \\> 80 U\u002Fl)\n* Elevated creatinine (double of normal range: \\>120 mmol\u002Fl))\n* ECOG ≥3\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has an impact on the prognosis of the patient\n* Inability to swallow tablets\n* Concurrent participation in another clinical trial on the same indication\n* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance","FEMALE","18 Years",{"count":200,"type":201},60,"ESTIMATED","INTERVENTIONAL",[204],"NA","The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.",[207,208,209,210],"Ovarian Neoplasm Epithelial","Fallopian Tube Neoplasms","Ovarian Endometrioid Carcinoma","High-grade Serous Ovarian Carcinoma (HGSOC)",[212,213,214,215,216,217,218,219],"Primary ovarian cancer (OC)","Treatment naiive","Multi-modal tumor profiling","Treatment recommendation process","Multi-disciplinary tumor board","Patient benefit","Quality of Life (QoL)","Patient-personalized therapy","2026-05-04",{"date":222,"type":223},"2026-05-05","ACTUAL",{"date":225,"type":223},"2025-03-31",{"date":227,"type":201},"2028-09",{"name":5,"class":6},7]